LCDR regulates the integrity of lysosomal membrane by hnRNP K–stabilized LAPTM5 transcript and promotes cell survival

Author:

Yang Xiwang123ORCID,Wen Ya13ORCID,Liu Shaomin4,Duan Liqiang3,Liu Tongfeng12,Tong Zhou3ORCID,Wang Zhuo3,Gu Yinmin2,Xi Yibo3,Wang Xiaodong2,Luo Dingsan2ORCID,Zhang Ruobing2,Liu Yajuan3,Wang Yang3,Cheng Tianyou3ORCID,Jiang Siyuan2,Zhu Xiaofeng13,Yang Xiaohui2ORCID,Pan Yongbo3,Cheng Shuwen5,Ye Qinong6,Chen Jinfei7ORCID,Xu Xiaoding4ORCID,Gao Shan238

Affiliation:

1. Medical School of Guizhou University, Guiyang 550025, China

2. CAS Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China

3. Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China

4. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

5. Cancer Center, Taikang Xianlin Drum Tower Hospital, Nanjing University School of Medicine, Nanjing 210046, China

6. Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine, Beijing 100850, China

7. Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

8. Zhongda Hospital, Southeast University, Nanjing 210096, China

Abstract

Significance Here, we report that the long noncoding RNA lysosome cell death regulator ( LCDR ) mediates the survival of cancer cells, counteracting the effects of apoptosis triggered by lysosomal cell death pathways. Mechanistically, LCDR , as a cofactor for heterogenous nuclear ribonucleoprotein K (hnRNP K) to potentiate the stabilization of lysosomal membrane protein lysosomal-associated protein transmembrane 5 (LAPTM5), prevents lysosomal membrane permeabilization and promotes cancer cell survival. Clinically, LCDR , hnRNP K, and LAPTM5 are significantly up-regulated in lung adenocarcinoma (LUAD) patients. Targeting LCDR via nanoparticles-mediated RNA interference technology increases cell death in vitro and inhibits the growth of patient-derived xenografts of LUAD in vivo. Our study demonstrates that LCDR contributes to cancer pathology by regulating LCDR -mediated apoptosis.

Funder

National Natural Science Foundation of China

Chinese Academy of Sciences

Technological Innovation Project of Shanxi Transformation and Comprehensive Reform Demonstration Zone

Technological Innovation Project key research project of Shanxi

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3